Amendment to EXCLUSIVE LICENSE AgreementTo Exclusive License Agreement • September 11th, 2017 • Galena Biopharma, Inc. • Pharmaceutical preparations
This Amendment to the Exclusive License Agreement, dated as of September 5, 2017 (the “Amendment”), by and between Mills Pharmaceuticals, LLC., a Delaware limited liability MPI (the “MPI”), and BioVascular, Inc., a Delaware MPI (the “BVI”), amends the Exclusive License Agreement, dated as of December 20, 2013, by and between the MPI and BVI (the “License Agreement”). Capitalized terms shall of the meaning set forth in the License Agreement unless otherwise set forth herein.
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENTTo Exclusive License Agreement • October 16th, 2015 • AveXis, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”) is entered into effective as of January 13, 2014 (the “Amendment Date”) by and between Nationwide Children’s Hospital, a nonprofit Ohio corporation (“Children’s”), and BioLife Cell Bank, Inc., a Delaware corporation (“Licensee”) (each a “Party” and collectively the “Parties”). This Amendment amends that certain Exclusive License Agreement (the “Original Agreement”) dated October 9, 2013 among the Parties. In the event of any conflict between the terms of the Original Agreement and the terms of this Amendment, the terms of this Amendment will control. Capitalized terms used but not defined herein shall have the respective meanings set forth in the Original Agreement.
AMENDMENT 1 TO EXCLUSIVE LICENSE AGREEMENTTo Exclusive License Agreement • March 13th, 2024 • Spero Therapeutics, Inc. • Pharmaceutical preparations
This Amendment 1 (“Amendment 1”) entered into as of July 4 2023 (“Amendment 1 Effective Date”), by and between Spero Therapeutics, Inc. (“Spero”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”), hereby amends the Exclusive License Agreement between the Parties dated September 21, 2022 (the “Agreement”). Capitalized terms not otherwise defined in this Amendment 1 will have the same meanings as ascribed to such terms in the Agreement.
AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENTTo Exclusive License Agreement • February 29th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTTo Exclusive License Agreement • November 13th, 2008 • Interleukin Genetics Inc • In vitro & in vivo diagnostic substances • Michigan
This First Amendment to Exclusive License Agreement (this “Amendment”) is made and entered into effective September 1, 2008, between Interleukin Genetics, Inc., a Delaware corporation having its principal office at 135 Beaver Street, Waltham, MA 02452 (“IG”) and Access Business Group International LLC, having offices at 7575 Fulton Street, East, Ada, Michigan 49355-001 (“ABG”).
